[go: up one dir, main page]

AR124246A1 - Polipéptidos de interleucina-2 mutante dependientes del ph - Google Patents

Polipéptidos de interleucina-2 mutante dependientes del ph

Info

Publication number
AR124246A1
AR124246A1 ARP210103369A ARP210103369A AR124246A1 AR 124246 A1 AR124246 A1 AR 124246A1 AR P210103369 A ARP210103369 A AR P210103369A AR P210103369 A ARP210103369 A AR P210103369A AR 124246 A1 AR124246 A1 AR 124246A1
Authority
AR
Argentina
Prior art keywords
receptor
polypeptides
dependent mutant
binding
immunoconjugates
Prior art date
Application number
ARP210103369A
Other languages
English (en)
Inventor
Lorenzo Deh
Christian Gassner
Sylvia Herter
Thomas Hofer
Ralf Hosse
Adrian Hugenmatter
Christian Klein
Florian Limani
Ekkehard Moessner
Melanie Obba
Bianca Scherer
Pablo Umaa
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR124246A1 publication Critical patent/AR124246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en general a polipéptidos de interleucina-2 mutante dependientes del pH que exhiben una unión reducida al receptor de IL-2 a pH neutro y retienen la unión al receptor de IL-2 a pH reducido. Además, la invención se refiere a inmunoconjugados que comprenden dichos polipéptidos de IL-2 mutante dependientes del pH, moléculas de polinucleótidos que codifican los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, y vectores y células huésped que comprenden tales moléculas de polinucleótidos. La invención se refiere además a métodos para producir los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, composiciones farmacéuticas que los comprenden y usos de estos. Reivindicación 1: Un polipéptido de interleucina-2 (IL-2) mutante que comprende una o más sustituciones de aminoácidos, cada una en comparación con una IL-2 de tipo silvestre, preferentemente IL-2 humana de acuerdo con SEQ ID Nº 144, en donde la una o más sustituciones de aminoácidos anulan o reducen la unión al receptor de IL-2, preferentemente al receptor de IL-2 de afinidad intermedia (IL2Rbg), a pH neutro y facilitan la unión al receptor de IL-2, preferentemente al receptor de IL-2 de afinidad intermedia (IL2Rbg), a pH disminuido.
ARP210103369A 2020-12-04 2021-12-03 Polipéptidos de interleucina-2 mutante dependientes del ph AR124246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20211731 2020-12-04

Publications (1)

Publication Number Publication Date
AR124246A1 true AR124246A1 (es) 2023-03-01

Family

ID=73726565

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP210103369A AR124246A1 (es) 2020-12-04 2021-12-03 Polipéptidos de interleucina-2 mutante dependientes del ph
ARP230100988A AR129131A2 (es) 2020-12-04 2023-04-24 POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230100988A AR129131A2 (es) 2020-12-04 2023-04-24 POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH

Country Status (15)

Country Link
US (1) US20240092853A1 (es)
EP (1) EP4255923A2 (es)
JP (1) JP2023551563A (es)
KR (1) KR20230117122A (es)
CN (1) CN116635403A (es)
AR (2) AR124246A1 (es)
AU (1) AU2021393752A1 (es)
CA (1) CA3197740A1 (es)
CO (1) CO2023007108A2 (es)
CR (1) CR20230219A (es)
IL (1) IL303381A (es)
MX (1) MX2023006480A (es)
PE (1) PE20232045A1 (es)
TW (1) TW202237632A (es)
WO (1) WO2022117692A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
CN101437847A (zh) 2006-05-08 2009-05-20 菲洛根有限公司 治疗用靶向细胞因子的抗体
WO2008034473A1 (de) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh Verfahren und vorrichtung zur trennung von methan und kohlendioxid aus biogas
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
NZ719654A (en) * 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
CN117003887A (zh) * 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物

Also Published As

Publication number Publication date
US20240092853A1 (en) 2024-03-21
KR20230117122A (ko) 2023-08-07
JP2023551563A (ja) 2023-12-08
AU2021393752A1 (en) 2023-05-18
CA3197740A1 (en) 2022-06-09
CN116635403A (zh) 2023-08-22
AR129131A2 (es) 2024-07-17
WO2022117692A2 (en) 2022-06-09
EP4255923A2 (en) 2023-10-11
MX2023006480A (es) 2023-06-19
CO2023007108A2 (es) 2023-06-30
IL303381A (en) 2023-08-01
WO2022117692A3 (en) 2022-10-20
CR20230219A (es) 2023-07-07
PE20232045A1 (es) 2023-12-27
TW202237632A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
AR129131A2 (es) POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH
AR114445A1 (es) Conjugados de il-15, y sus usos
AR126987A2 (es) Inmunoconjugados
MX2021007085A (es) Variante de interleucina-2 humana o derivado de la misma.
SA521422581B1 (ar) أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها
CN112105633A (zh) 新型白介素2及其用途
JP2019122392A5 (es)
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CL2024000834A1 (es) Proteína mutante de interleucina-2 y fusión de la misma
NO20055852L (no) Nye peptider som binder til erytropoietinreseptoren
BR112022020629A2 (pt) Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
ES2639039T3 (es) Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico
BR112022020796A2 (pt) Polipeptídeos de interleucina-22 projetados e usos do mesmos
PE20230486A1 (es) Polipeptidos y sus usos
BR112022011158A2 (pt) Vírus vaccinia oncolítico variante e métodos de uso do mesmo
CO2023000048A2 (es) Conjugados de citoquina
ATE349468T1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
JP2008542311A5 (es)
Cao et al. Characterization, cloning and expression of the 67-kDA annexin from chicken growth plate cartilage matrix vesicles
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
WO2024178000A3 (en) Polynucleotides encoding modified interleukin 2 (il2) polypeptides, and methods of making and using the same
BR112022003705A2 (pt) Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal